[1] ZORZAN M, GIORDAN E, REDAELLI M, et al. Molecular targets in glioblastoma[J]. Future Oncol, 2015,11(9):1407-1420. [2] PREUSSER M, DE RIBAUPIERRE S, WÖHRER A, et al. Current concepts and management of glioblastoma[J].Ann Neurol, 2011,70(1):9-21. [3] ANDREWS FH, SINGH AR, JOSHI S, et al. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis[J]. Proc Natl Acad Sci U S A, 2017,114(7):E1072-E1080. [4] ZHU J X, XIAO J R. SF2523 inhibits human chondrosarcoma cell growth in vitro and in vivo[J]. Biochem Biophys Res Commun, 2019,511(3):559-565. [5] SHEN G, JIANG M, PU J. Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth in vitro and in vivo[J]. Biochem Biophys Res Commun,2018,495(1):567-573. [6] LOUIS D N, OHGAKI H, WIESTLER O D, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol,2007,114(2):97-109. [7] ALCANTARA LLAGUNO S R, PARADA L F. Cell of origin of glioma: biological and clinical implications[J].Br J Cancer,2016,115(12):1445-1450. [8] STUPP R, HEGI M E, MASON W P, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study: 5-year analysis of the EORTC-NCIC trial[J]. Lancet Oncol, 2009,10(5):459-466. [9] HOMBACH-KLONISCH S, MEHRPOUR M, SHOJAEI S, et al. Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response[J]. Pharmacol Ther, 2018,184:13-41. [10] OSUKA S, VAN MEIR E G. Overcoming therapeutic resistance in glioblastoma: the way forward[J].J Clin Invest, 2017,127(2):415-426. [11] RYSKALIN L, GAGLIONE A, LIMANAQI F,et al. The autophagy status of cancer stem cells in gliobastoma multiforme: from cancer promotion to therapeutic strategies[J]. Int J Mol Sci,2019,20(15):E3824. [12] BAYIN N S, MODREK A S, PLACANTONAKIS D G. Glioblastoma stem cells: Molecular characteristics and therapeutic implications[J]. World J Stem Cells, 2014,6(2):230-238. [13] LUDWIG K, KORNBLUM H I. Molecular markers in glioma[J]. J Neurooncol,2017,134(3):505-512. [14] SINGH S K, HAWKINS C, CLARKE I D, et al. Identification of human brain tumour initiating cells[J]. Nature, 2004,432(7015):396-401. [15] LEAL A S, WILLIAMS C R, ROYCE D B, et al. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer[J].Cancer Lett, 2017,394:76-87. [16] JOSHI S, SINGH A R, LIU K X, et al. SF2523: Dual PI3K/BRD4 inhibitor blocks tumor immunosuppression and promotes adaptive immune responses in cancer[J]. Mol Cancer Ther, 2019,18(6):1036-1044. [17] SU J, LIU XG, ZHANG SL, et al. A theoretical insight into selectivity of inhibitors toward two domains of bromodomain-containing protein 4 using molecular dynamics simulations[J]. Chem Biol Drug Des, 2018,91(3):828-840. [18] ZHU H, MAO J H, WANG Y, et al. Dual inhibition of BRD4 and PI3K-AKT by SF2523 suppresses human renal cell carcinoma cell growth[J]. Oncotarget, 2017,8(58):98471-98481. [19] URREGO D, TOMCZAK A P, ZAHED F, et al. Potassium channels in cell cycle and cell proliferation[J]. Philos Trans R Soc Lond B Biol Sci, 2014,369(1638):20130094. [20] KACZANOWSKI S. Apoptosis: its origin, history, maintenance and the medical implications for cancer and aging[J]. Phys Biol,2016,13(3):031001. [21] PENA-BLANCO A, GARCIA-SAEZ A J. Bax, Bak and beyond-mitochondrial performance in apoptosis[J]. FEBS J, 2018,285(3):416-431. [22] 陈雪,张玉影,邵玉,等. 五味子甲素对脑胶质瘤C6细胞生长的抑制作用及其机制[J]. 吉林大学学报:医学版,2016,42(4):711-715. [23] 王莹,宋凡.富亮氨酸胶质瘤失活1蛋白抗体相关自身免疫性脑炎6例临床分析[J].中国实用内科杂志,2018,38(8):749-752. |